Prognosis

COVID-19 Severity and Risk Predicted by New Metabolism-Based Blood Test

Wednesday, December 1, 2021 - 8:25pm

Blood samples were obtained from each patient and studied for biochemical composition using quantitative mass spectrometry.

Key Points: 
  • Blood samples were obtained from each patient and studied for biochemical composition using quantitative mass spectrometry.
  • This technique allowed researchers to measure minute quantities of metabolites in the blood.
  • Investigators identified metabolic signatures that could distinguish mild COVID-19 infection from more severe and lethal forms of the disease.
  • Metabolomycs, Inc is a California-based corporation that applies metabolic signatures measured by mass spectrometry to study human health and disease.

75 Years of Help, Hope and Answers

Wednesday, December 1, 2021 - 6:52pm

Disability is a broad term that covers those that use wheelchairs, but also the preemie with a developmental delay, the child with Down syndrome, the teen with autism that needs help entering the workforce, the adult with cerebral palsy that has aged out of most programming, the veteran struggling to reenter civilian life, and more. These stories and people surround us--they're your coworker's daughter, elderly neighbor, friend's spouse and more depending on ESGH's programming. Disability touches each and every person's life and therefore investing in disability resources uplifts us all.

Key Points: 
  • Originally called the Cerebral Palsy Treatment Center, the non-profit's programing, reach, and expertise have grown substantially since its inception in 1947.
  • Today, over 14,500 babies, children and adults with disabilities, Veterans, service members, and their families rely on the agency's life-changing services and resources annually.
  • In celebration of being the community partner for help, hope and answers in disability services for 75 years, ESGH is highlighting their clients' successes over the years, their hard-working staff, and key community partners.
  • As the need for ESGH's crucial services grows, the agency is calling on its neighbors to donate $75 for 75 years of vital programming.

Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Research at Virtual 32nd International Symposium on ALS/MND

Wednesday, December 1, 2021 - 2:00pm

The U.S. Food and Drug Administration (FDA) approved RADICAVA(edaravone) IV on May 5, 2017 as a treatment for amyotrophic lateral sclerosis (ALS).1Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Tanabe Pharma Development America, Inc. (MTDA), commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) approved RADICAVA(edaravone) IV on May 5, 2017 as a treatment for amyotrophic lateral sclerosis (ALS).1Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Tanabe Pharma Development America, Inc. (MTDA), commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc.
  • About Mitsubishi Tanabe Pharma America, Inc.
    Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc.
  • The U.S. headquarters of Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) is located in Jersey City, New Jersey.
  • MTDA is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's 100 percent-owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTDA is dedicated to research and develop innovative pharmaceutical products that address the unmet medical needs of patients.

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan

Wednesday, December 1, 2021 - 1:54pm

SHENZHEN, China, Dec. 1, 2021 /PRNewswire/ --Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza, Hiyasta, HBI-8000) monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan.

Key Points: 
  • SHENZHEN, China, Dec. 1, 2021 /PRNewswire/ --Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza, Hiyasta, HBI-8000) monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan.
  • These patients, having few effective treatment options, all had advanced disease either refractory to or relapsed to prior therapies.
  • About Chidamide (also known as Epidaza, Hiyasta, HBI-8000)
    Chidamide is a first-in-class/best-in-class innovative drug which was discovered and developed originally by Shenzhen Chipscreen Biosciences in China.
  • Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) was founded inShenzhenin 2001, specializing in the research and development of novel small molecule drugs.

Neuvivo Launches to Develop and Market Effective and Safe Treatments for ALS

Wednesday, December 1, 2021 - 1:30pm

Neuvivo's leadcandidate, NP001, has received Orphan Drug and Fast Track designation by the FDA for use in ALS.

Key Points: 
  • Neuvivo's leadcandidate, NP001, has received Orphan Drug and Fast Track designation by the FDA for use in ALS.
  • Neuvivo is bringing together a powerhouse team to carry forward its mission, including seasoned industry executives, clinicians, and pioneer scientists with extensive backgrounds in ALS research and multiple product approval successes.
  • "We know now that chronic inflammation is a key factor in the loss of motor neuron function in ALS.
  • About Neuvivo: Neuvivo is a private biopharmaceutical company focused on creating and delivering advanced treatments for ALS and other neurodegenerative diseases.

Genomic Testing Cooperative to Present data at the American Society of Hematology Meeting on its Proprietary Machine Learning Approaches for RNA Transcriptome Data and on the Use of Liquid Biopsy

Wednesday, December 1, 2021 - 12:00pm

GTC is the only diagnostic company that offers molecular testing based on cooperative (Co-Op) business model.

Key Points: 
  • GTC is the only diagnostic company that offers molecular testing based on cooperative (Co-Op) business model.
  • GTC uses RNA data and targeted transcriptome generated by next generation sequencing (NGS) along with new machine learning approaches to predict the presence of aGVHD and for stratifying patients with DLBCL.
  • GTC is developing new indications in liquid biopsy testing and extensively exploring new technology to improve patient care.
  • He added, Advances in genomics and machine learning are opening new opportunities in medicine to improve outcome in cancer care.

Worldwide Autonomous Technology Industry to 2028 - Proliferation of Automotive Electronics Presents Opportunities - ResearchAndMarkets.com

Wednesday, December 1, 2021 - 10:03am

These factors; the market dynamics, involves the drivers, restraints, opportunities and challenges through which the impact of these factors in the market are outlined.

Key Points: 
  • These factors; the market dynamics, involves the drivers, restraints, opportunities and challenges through which the impact of these factors in the market are outlined.
  • The drivers and restraints are intrinsic factors whereas opportunities and challenges are extrinsic factors of the market.
  • The Autonomous Technology Market study provides an outlook on the development of market in terms of revenue throughout the prognosis period.
  • The report also focuses on the competitive landscape of the Autonomous Technology Market.

Insights on the Digital Utility Global Market to 2027 - Players Include Microsoft, General Electric and IBM Among Others - ResearchAndMarkets.com

Wednesday, December 1, 2021 - 9:56am

The Digital Utility Market report provides a holistic evaluation of the market for the forecast period.

Key Points: 
  • The Digital Utility Market report provides a holistic evaluation of the market for the forecast period.
  • The Digital Utility Market study provides an outlook on the development of market in terms of revenue throughout the prognosis period.
  • Increasing number of distributed and renewable power generation projects is a key element that has boosted the growth of Digital Utility market.
  • The report also focuses on the competitive landscape of the Digital Utility Market.

Deep Bio and Tribun Health Join Forces to Enhance Cancer Care with AI-Powered Digital Pathology

Wednesday, December 1, 2021 - 3:00am

Under the agreement, the two companies will harness the power of AI in digital pathology to improve cancer patient care.

Key Points: 
  • Under the agreement, the two companies will harness the power of AI in digital pathology to improve cancer patient care.
  • DeepDx Prostate, Deep Bio's deep learning-based prostate cancer diagnostic support software, aids pathologists in making fast and consistent diagnostic decisions for prostate cancer.
  • Recently, Tribun Health unveiled the "Tribun Health Platform", with at its core, CaloPix, the gold standard in Image Management and analysis for pathology.
  • Deep Bio Inc. is an AI biotech company with in-house expertise in deep learning, pathology, life sciences, and pharmacotherapeutics.

Global Smart Motors Market (2021 to 2028) - by Type, Application and Geographic Scope - ResearchAndMarkets.com

Tuesday, November 30, 2021 - 6:37pm

The Smart Motors Market report provides a holistic evaluation of the market for the forecast period.

Key Points: 
  • The Smart Motors Market report provides a holistic evaluation of the market for the forecast period.
  • The Smart Motors Market study provides an outlook on the development of market in terms of revenue throughout the prognosis period.
  • These market estimates have been considered by studying the impact of various social, political and economic factors along with the current market dynamics affecting the Smart Motors Market growth.
  • The report also focuses on the competitive landscape of the Smart Motors Market.